- Maropitant Citrate
-
-
2026-09-11
- CAS:359875-09-5
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 20
- Maropitant Citrate
-
-
2026-09-11
- CAS:359875-09-5
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| | Maropitant citrate hydrate Basic information |
| Product Name: | Maropitant citrate hydrate | | Synonyms: | ACIDUM CITRICUM ANHYDRICUM;B-HYDROXYTRICARBALLYLIC ACID;HYDROXYTRICARBALLYLIC ACID;CEFIXIM TELLURITE SUPPLEMENT;CITRATE ION CHROMATOGRAPHY STANDARD;CT SUPPLEMENT;TELLURITE CEFIXIM SUPPLEMENT;TIMTEC-BB SBB008922 | | CAS: | 359875-09-5 | | MF: | C38H48N2O8 | | MW: | 660.81 | | EINECS: | 201-069-1 | | Product Categories: | API;API;359875-09-5 | | Mol File: | 359875-09-5.mol |  |
| | Maropitant citrate hydrate Chemical Properties |
| Melting point | 153-159 °C(lit.) | | Fp | 100 °C | | storage temp. | 2-8°C | | solubility | H2O: 1 M at 20 °C, clear, colorless | | form | white to off-white crystalline powder | | Water Solubility | Water: 3 mg/mL (4.42 mM) | | Major Application | agriculture
environmental
food and beverages || microbiology | | InChIKey | XDZPFSKCXRGRIO-OHTRWSNQNA-N | | SMILES | C(O)(C(=O)O)(CC(=O)O)CC(=O)O.C(C1C=CC=CC=1)(C1C=CC=CC=1)[C@@H]1N2CCC(CC2)[C@@H]1NCC1C=C(C(C)(C)C)C=CC=1OC |&1:26,33,r| | | CAS DataBase Reference | 359875-09-5(CAS DataBase Reference) |
| Hazard Codes | Xi,T | | Risk Statements | 41-42/43-36/37/38-25 | | Safety Statements | 26-39-45-36/37-22 | | RIDADR | UN 3284 6.1/PG 3 | | WGK Germany | 1 | | RTECS | GE7350000 | | F | 9 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral
Eye Irrit. 2
Skin Irrit. 2
Skin Sens. 1 |
| | Maropitant citrate hydrate Usage And Synthesis |
| Description | Maropitant citrate hydrate is a specific neurokinin-1 (NK-1) receptor antagonist that selectively inhibits the production of substance P, a mediator involved in signalling vomiting. Maropitant citrate was therefore originally used to treat vomiting in dogs and cats. Currently, it is also used as an adjunct to visceral analgesia in dogs and cats, and in other species such as horses and birds. | | Uses | Anti-emetic. | | Pharmacokinetics | The maximum, minimum, and average concentrations of maropitant achieved at steady state were 375.5 ± 200, 16.8 ± 7.7, and 73.5 ± 45.1 ng/ml, respectively. The terminal elimination half-life was 11.6 ± 1.4 hr, and the accumulation index was 1.3 ± 0.07. Heart rate decreased between Day 1 and Day 5 (p = .005), with three horses having heart rates of 20 beats per minute and atrioventricular block on Day 5. Pharmacokinetics of repeated maropitant administration suggests the drug could be considered for use in healthy horses. | | Veterinary Drugs and Treatments | Maropitant citrate injectable solution is indicated for the prevention
and treatment of acute vomiting in dogs; maropitant citrate
tablets are indicated for the prevention of acute vomiting and the
prevention of vomiting due to motion sickness in dogs. Both are
also used extra-label in cats. |
| | Maropitant citrate hydrate Preparation Products And Raw materials |
|